Followers | 245 |
Posts | 49722 |
Boards Moderated | 69 |
Alias Born | 08/29/2007 |
Saturday, March 16, 2024 2:48:45 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent CGTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:11:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/11/2024 08:06:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:44:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:13:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:13:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2024 12:12:08 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/19/2024 08:07:49 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/09/2024 05:15:26 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/08/2024 09:11:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:21:33 PM
- Cognition Therapeutics CEO Issues Letter to Shareholders • GlobeNewswire Inc. • 01/04/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 09:02:07 PM
- Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens • GlobeNewswire Inc. • 11/16/2023 12:30:35 PM
- Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases • GlobeNewswire Inc. • 11/15/2023 12:30:48 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/13/2023 10:25:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 02:48:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 02:47:16 PM
- Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease • GlobeNewswire Inc. • 11/07/2023 12:30:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 11:45:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 11:41:02 AM
- Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/02/2023 11:30:00 AM
- Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD • GlobeNewswire Inc. • 10/27/2023 11:30:15 AM
- Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD • GlobeNewswire Inc. • 10/24/2023 08:30:41 PM
- Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications • GlobeNewswire Inc. • 10/16/2023 11:30:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM